Intravenous immunoglobulin treatment for long COVID: a case report of clinical and immunological findings - PubMed
6 hours ago
- #intravenous immunoglobulin
- #long COVID
- #immunomodulation
- A 39-year-old man with severe long COVID symptoms, including cognitive dysfunction and fatigue, received high-dose intravenous immunoglobulin (IVIG) therapy.
- Treatment involved initial and maintenance IVIG doses over several cycles, leading to normalization of fatigue scores, neurocognitive recovery, and improved quality of life within a year.
- Immunological changes observed included a persistent inverted CD4 to CD8 T-cell ratio and a reduction in CD8+ T cell-monocyte complexes, IFNγ/TNF production, endothelial inflammation markers, and autoantibody titers.
- The case suggests IVIG may modulate post-viral immune dysregulation in long COVID, warranting further evaluation as a potential therapeutic approach in selected patients.